Appili Therapeutics Inc experiences notable price fluctuations amidst recent developments.
This week, Appili Therapeutics Inc (APLI.TO) saw a substantial uptick in its stock price, rising 50% over the past week. The latest trading session closed flat at C$0.01, but the stock has shown signs of volatility and investor interest in recent days.
Investor takeaway: Investors should consider the implications of recent operational updates and financial results while weighing the stock's technical indicators and overall market sentiment.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+50.00%
Beta
-0.21
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
207.3%
Annualized
90-Day Vol
222.9%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.01 – C$0.03 |
| 60 trading days | C$0.02 | C$0.01 – C$0.04 |
| 90 trading days | C$0.02 | C$0.00 – C$0.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
C$0.01 closing price with a 50% increase over the past week.
The stock's trading volume has been notably low, at just 2,500 shares compared to a 20-day average of 69,131 shares, suggesting a lack of broad market participation.
Bull case
The company has made significant strides with its product LIKMEZ® (ATI-1501) in the U.S. This progress could lead to future revenue growth and attract more investor interest.
Bear case
Despite the recent price increase, Appili’s financial health raises concerns. The company has a negative return on equity and a low profit margin, which indicate ongoing challenges.
Recent Price Action
Advertisement
Appili Therapeutics Inc closed the last trading session at C$0.01, with no change from the previous day. Over the past week, however, the stock has surged by 50%, indicating heightened investor interest and potential market activity.
Company News and Developments
Appili recently announced its fiscal year 2026 financial and operational results, highlighting progress with LIKMEZ® (ATI-1501) in the U.S. market and securing a US$40 million NIAID award for the advancement of VXV-01. However, the company also received a termination notice from NIAID regarding the VXV-01 program, effective July 3, 2026, which could impact future funding and project timelines.
Technical Picture
Currently, Appili's stock trades at C$0.01, which is at the lower end of its 52-week range of C$0.01 to C$0.04. The 50-day moving average stands at C$0.01, reflecting a slight increase of 1.4% compared to the current price. In contrast, the 200-day moving average is at C$0.02, indicating a 23.5% decline from the price. The stock has a beta of -0.21, suggesting that it is less volatile than the broader market. The latest trading volume was 2,500 shares, significantly lower than the 20-day average volume of 69,131 shares.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
